Details of the Drug

General Information of Drug (ID: DMGLX0T)

Drug Name
Grepafloxacin
Synonyms
Raxar; Grepafloxacin [INN]; Grepafloxacin (unspecified); Raxar (TN); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Chronic bronchitis CA20.1 Approved [1]
Bacterial infection 1A00-1C4Z Withdrawn from market [2]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 359.4
Topological Polar Surface Area (xlogp) -0.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Bioavailability
The bioavailability of drug is 70% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.9 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 +/- 3 hours [4]
Metabolism
The drug is metabolized via the hepatic [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.82% [4]
Chemical Identifiers
Formula
C19H22FN3O3
IUPAC Name
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
InChI
InChI=1S/C19H22FN3O3/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26)
InChIKey
AIJTTZAVMXIJGM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
72474
ChEBI ID
CHEBI:5543
CAS Number
119914-60-2
DrugBank ID
DB00365
TTD ID
D0JL2K
VARIDT ID
DR00638
INTEDE ID
DR0790

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [6]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [7]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Grepafloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Tretinoin DM49DUI Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Tretinoin. Acne vulgaris [ED80] [79]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [80]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [81]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Daunorubicin. Acute myeloid leukaemia [2A60] [81]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Arn-509. Acute myeloid leukaemia [2A60] [81]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [81]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Oliceridine. Acute pain [MG31] [80]
Magnesium Sulfate DMVEK07 Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Magnesium Sulfate. Acute pain [MG31] [82]
Loratadine DMF3AN7 Moderate Decreased metabolism of Grepafloxacin caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [83]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Galantamine. Alzheimer disease [8A20] [84]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Rivastigmine. Alzheimer disease [8A20] [84]
Donepezil DMIYG7Z Moderate Decreased metabolism of Grepafloxacin caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [83]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Grepafloxacin and Metronidazole. Amoebiasis [1A36] [80]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Ivabradine. Angina pectoris [BA40] [85]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Dronedarone. Angina pectoris [BA40] [84]
Nifedipine DMSVOZT Moderate Decreased metabolism of Grepafloxacin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [83]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [81]
Clorazepate DMC3JST Moderate Decreased metabolism of Grepafloxacin caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [83]
Alprazolam DMC7XDN Moderate Decreased metabolism of Grepafloxacin caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [83]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [81]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Grepafloxacin caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [83]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Cilostazol. Arterial occlusive disease [BD40] [81]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Voriconazole. Aspergillosis [1F20] [81]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Posaconazole. Aspergillosis [1F20] [81]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Levalbuterol. Asthma [CA23] [86]
Terbutaline DMD4381 Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Terbutaline. Asthma [CA23] [87]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Pirbuterol. Asthma [CA23] [86]
Budesonide DMJIBAW Moderate Decreased metabolism of Grepafloxacin caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [88]
Aminophylline DML2NIB Moderate Decreased metabolism of Grepafloxacin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [89]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Salbutamol. Asthma [CA23] [90]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Grepafloxacin caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [85]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Formoterol. Asthma [CA23] [87]
Zileuton DMVRIC2 Moderate Decreased metabolism of Grepafloxacin caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [83]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [81]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Desipramine. Attention deficit hyperactivity disorder [6A05] [81]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Clarithromycin. Bacterial infection [1A00-1C4Z] [81]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Grepafloxacin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [84]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Telithromycin. Bacterial infection [1A00-1C4Z] [80]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Retigabine. Behcet disease [4A62] [80]
Cariprazine DMJYDVK Moderate Decreased metabolism of Grepafloxacin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [85]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Loperamide. Bowel habit change [ME05] [91]
Temozolomide DMKECZD Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [79]
Lomustine DMMWSUL Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [79]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Eribulin. Breast cancer [2C60-2C6Y] [81]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Grepafloxacin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [92]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [81]
Palbociclib DMD7L94 Moderate Decreased metabolism of Grepafloxacin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [85]
Thiotepa DMIZKOP Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [79]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Grepafloxacin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [93]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Toremifene. Breast cancer [2C60-2C6Y] [81]
Bosutinib DMTI8YE Moderate Decreased clearance of Grepafloxacin due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [85]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Sotalol. Cardiac arrhythmia [BC9Z] [81]
Atorvastatin DMF28YC Moderate Decreased metabolism of Grepafloxacin caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [94]
Macitentan DMP79A1 Moderate Decreased metabolism of Grepafloxacin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [95]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [80]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [87]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [86]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [87]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [87]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [87]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Grepafloxacin and Ketoprofen. Chronic pain [MG30] [96]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Grepafloxacin caused by Irinotecan mediated inhibition of UGT. Colorectal cancer [2B91] [84]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Oxaliplatin. Colorectal cancer [2B91] [81]
Capecitabine DMTS85L Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [79]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Isoproterenol. Conduction disorder [BC63] [87]
Ulipristal DMBNI20 Minor Decreased metabolism of Grepafloxacin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [85]
Mestranol DMG3F94 Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [97]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Halothane. Corneal disease [9A76-9A78] [81]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Propofol. Corneal disease [9A76-9A78] [98]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Sevoflurane. Corneal disease [9A76-9A78] [81]
Cocaine DMSOX7I Moderate Decreased metabolism of Grepafloxacin caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [83]
Alfentanil DMVO0UB Moderate Decreased metabolism of Grepafloxacin caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [99]
Nimodipine DMQ0RKZ Moderate Decreased metabolism of Grepafloxacin caused by Nimodipine mediated inhibition of CYP450 enzyme. Coronary vasospastic disease [BA85] [83]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Clofazimine. Crohn disease [DD70] [80]
Mycophenolic acid DMU65NK Moderate Altered absorption of Grepafloxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [100]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Mifepristone. Cushing syndrome [5A70] [84]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Pasireotide. Cushing syndrome [5A70] [81]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Osilodrostat. Cushing syndrome [5A70] [80]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Grepafloxacin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [101]
Aprepitant DM053KT Moderate Decreased metabolism of Grepafloxacin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [102]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Sertraline. Depression [6A70-6A7Z] [81]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Trimipramine. Depression [6A70-6A7Z] [81]
Cyclobenzaprine DM1YBRM Moderate Decreased metabolism of Grepafloxacin caused by Cyclobenzaprine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Imipramine. Depression [6A70-6A7Z] [81]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Fluoxetine. Depression [6A70-6A7Z] [81]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Nortriptyline. Depression [6A70-6A7Z] [81]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Grepafloxacin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [83]
Duloxetine DM9BI7M Moderate Decreased metabolism of Grepafloxacin caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [103]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Escitalopram. Depression [6A70-6A7Z] [81]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Clomipramine. Depression [6A70-6A7Z] [81]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Trazodone. Depression [6A70-6A7Z] [81]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Amoxapine. Depression [6A70-6A7Z] [81]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Mirtazapine. Depression [6A70-6A7Z] [81]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Doxepin. Depression [6A70-6A7Z] [81]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Maprotiline. Depression [6A70-6A7Z] [81]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Grepafloxacin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [104]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [81]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Deutetrabenazine. Dystonic disorder [8A02] [81]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ingrezza. Dystonic disorder [8A02] [81]
Diazepam DM08E9O Moderate Decreased metabolism of Grepafloxacin caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Grepafloxacin caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [105]
Ethosuximide DMDZ9LT Moderate Decreased metabolism of Grepafloxacin caused by Ethosuximide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Grepafloxacin caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Clonazepam DMTO13J Moderate Decreased metabolism of Grepafloxacin caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Carbamazepine DMZOLBI Moderate Decreased metabolism of Grepafloxacin caused by Carbamazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Grepafloxacin caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [83]
Mefenamic acid DMK7HFI Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Mefenamic acid. Female pelvic pain [GA34] [96]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Solifenacin. Functional bladder disorder [GC50] [81]
Mirabegron DMS1GYT Minor Decreased metabolism of Grepafloxacin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [106]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Grepafloxacin caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [107]
Itraconazole DMCR1MV Moderate Decreased metabolism of Grepafloxacin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [83]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Pentamidine. Fungal infection [1F29-1F2F] [81]
Miconazole DMPMYE8 Moderate Decreased metabolism of Grepafloxacin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [83]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ketoconazole. Fungal infection [1F29-1F2F] [81]
Ripretinib DM958QB Moderate Decreased metabolism of Grepafloxacin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [80]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [81]
Avapritinib DMK2GZX Moderate Decreased metabolism of Grepafloxacin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [85]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Grepafloxacin caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [108]
Procarbazine DMIK367 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [79]
MK-1439 DM215WE Minor Decreased metabolism of Grepafloxacin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [109]
Delavirdine DM3NF5G Moderate Decreased metabolism of Grepafloxacin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [80]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [81]
Dolutegravir DMCZGRE Minor Decreased metabolism of Grepafloxacin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Didanosine DMI2QPE Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [111]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [80]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [81]
Ritonavir DMU764S Moderate Decreased metabolism of Grepafloxacin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [112]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Grepafloxacin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [113]
Losartan DM72JXH Moderate Decreased metabolism of Grepafloxacin caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Nisoldipine DM7ISKJ Moderate Decreased metabolism of Grepafloxacin caused by Nisoldipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Levamlodipine DM92S6N Moderate Decreased metabolism of Grepafloxacin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Verapamil DMA7PEW Moderate Decreased metabolism of Grepafloxacin caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Amlodipine DMBDAZV Moderate Decreased metabolism of Grepafloxacin caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Felodipine DMOSW35 Moderate Decreased metabolism of Grepafloxacin caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Fludrocortisone DMUDIR8 Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [114]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [115]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Grepafloxacin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [80]
Ramelteon DM7IW9J Moderate Decreased metabolism of Grepafloxacin caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [116]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Grepafloxacin caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
Triazolam DMETYK5 Moderate Decreased metabolism of Grepafloxacin caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
Melatonin DMKWFBT Moderate Decreased metabolism of Grepafloxacin caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Grepafloxacin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Grepafloxacin caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [118]
Estazolam DMZGXUM Moderate Decreased metabolism of Grepafloxacin caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [83]
Iron DMAP8MV Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [119]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [120]
Alosetron DML2A03 Moderate Decreased metabolism of Grepafloxacin caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [121]
Pemigatinib DM819JF Moderate Decreased metabolism of Grepafloxacin caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [122]
Testosterone DM7HUNW Moderate Decreased metabolism of Grepafloxacin caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [83]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Crizotinib. Lung cancer [2C25] [81]
Brigatinib DM7W94S Moderate Decreased metabolism of Grepafloxacin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [80]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ceritinib. Lung cancer [2C25] [81]
Erlotinib DMCMBHA Moderate Decreased metabolism of Grepafloxacin caused by Erlotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [123]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Grepafloxacin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [124]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Osimertinib. Lung cancer [2C25] [81]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Grepafloxacin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [125]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Selpercatinib. Lung cancer [2C25] [80]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lumefantrine. Malaria [1F40-1F45] [80]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Chloroquine. Malaria [1F40-1F45] [81]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [81]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Quinine. Malaria [1F40-1F45] [81]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Primaquine. Malaria [1F40-1F45] [81]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [81]
Fludarabine DMVRLT7 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [79]
Pentostatin DM0HXDS Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Pentostatin. Mature B-cell leukaemia [2A82] [79]
Idelalisib DM602WT Moderate Decreased clearance of Grepafloxacin due to the transporter inhibition by Idelalisib. Mature B-cell leukaemia [2A82] [126]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Grepafloxacin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [80]
IPI-145 DMWA24P Moderate Decreased metabolism of Grepafloxacin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [127]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [81]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Grepafloxacin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [128]
Clofarabine DMCVJ86 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Clofarabine. Mature B-cell lymphoma [2A85] [79]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Grepafloxacin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [129]
Vincristine DMINOX3 Moderate Decreased metabolism of Grepafloxacin caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [83]
Teniposide DMLW57T Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Teniposide. Mature B-cell lymphoma [2A85] [79]
Mercaptopurine DMTM2IK Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [79]
Cytarabine DMZD5QR Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [79]
Mechlorethamine DM0CVXA Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [79]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Vemurafenib. Melanoma [2C30] [81]
Selumetinib DMC7W6R Moderate Decreased metabolism of Grepafloxacin caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [130]
Dacarbazine DMNPZL4 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [79]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and LGX818. Melanoma [2C30] [81]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [97]
Ubrogepant DM749I3 Moderate Decreased metabolism of Grepafloxacin caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [131]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Grepafloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [84]
Midazolam DMXOELT Moderate Decreased metabolism of Grepafloxacin caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [83]
Riluzole DMECBWN Minor Decreased metabolism of Grepafloxacin caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [132]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Panobinostat. Multiple myeloma [2A83] [81]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Thalidomide. Multiple myeloma [2A83] [80]
Melphalan DMOLNHF Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [79]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Siponimod. Multiple sclerosis [8A40] [80]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Fingolimod. Multiple sclerosis [8A40] [84]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ozanimod. Multiple sclerosis [8A40] [81]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Grepafloxacin and Methoxsalen. Mycosis fungoides [2B01] [80]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Romidepsin. Mycosis fungoides [2B01] [80]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Nilotinib. Myeloproliferative neoplasm [2A20] [81]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Grepafloxacin caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [85]
Imatinib DM7RJXL Moderate Decreased metabolism of Grepafloxacin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [133]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [81]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [79]
Busulfan DMXYJ9C Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [79]
Modafinil DMYILBE Minor Decreased metabolism of Grepafloxacin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [80]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Droperidol. Nausea/vomiting [MD90] [81]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Prochlorperazine. Nausea/vomiting [MD90] [81]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Promethazine. Nausea/vomiting [MD90] [81]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Palonosetron. Nausea/vomiting [MD90] [81]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Granisetron. Nausea/vomiting [MD90] [81]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Dolasetron. Nausea/vomiting [MD90] [81]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Ondansetron. Nausea/vomiting [MD90] [81]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Grepafloxacin and Bupropion. Nicotine use disorder [6C4A] [134]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Entrectinib. Non-small cell lung cancer [2C25] [80]
Sibutramine DMFJTDI Minor Decreased metabolism of Grepafloxacin caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [135]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lofexidine. Opioid use disorder [6C43] [81]
Diclofenac DMPIHLS Moderate Additive CNS depression effects by the combination of Grepafloxacin and Diclofenac. Osteoarthritis [FA00-FA05] [96]
Naproxen DMZ5RGV Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Naproxen. Osteoarthritis [FA00-FA05] [96]
Olaparib DM8QB1D Moderate Decreased metabolism of Grepafloxacin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [136]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Rucaparib. Ovarian cancer [2C73] [81]
Carboplatin DMG281S Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Carboplatin. Ovarian cancer [2C73] [79]
Altretamine DMKLAYG Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Altretamine. Ovarian cancer [2C73] [79]
Topotecan DMP6G8T Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [79]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Dextropropoxyphene. Pain [MG30-MG3Z] [80]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Aspirin. Pain [MG30-MG3Z] [115]
Etodolac DM6WJO9 Moderate Additive CNS depression effects by the combination of Grepafloxacin and Etodolac. Pain [MG30-MG3Z] [96]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Grepafloxacin and Diflunisal. Pain [MG30-MG3Z] [96]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Grepafloxacin and Ibuprofen. Pain [MG30-MG3Z] [96]
Nabumetone DMAT2XH Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Nabumetone. Pain [MG30-MG3Z] [96]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Buprenorphine. Pain [MG30-MG3Z] [81]
Piroxicam DMTK234 Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Piroxicam. Pain [MG30-MG3Z] [96]
Oxycodone DMXLKHV Moderate Decreased metabolism of Grepafloxacin caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [80]
Streptozocin DMOF7AT Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Streptozocin. Pancreatic cancer [2C10] [79]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Grepafloxacin caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [83]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Triclabendazole. Parasitic worm infestation [1F90] [80]
Albendazole DMYZ57N Moderate Decreased metabolism of Grepafloxacin caused by Albendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [83]
Rasagiline DM3WKQ4 Major Decreased metabolism of Grepafloxacin caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [80]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Pimavanserin. Parkinsonism [8A00] [81]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Grepafloxacin caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [83]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Apomorphine. Parkinsonism [8A00] [81]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Grepafloxacin and Lindane. Pediculosis [1G00] [137]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Grepafloxacin and Famotidine. Peptic ulcer [DA61] [80]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [138]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lefamulin. Pneumonia [CA40] [80]
Prednisone DM2HG4X Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Prednisone. Postoperative inflammation [1A00-CA43] [114]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [115]
Betamethasone DMAHJEF Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Betamethasone. Postoperative inflammation [1A00-CA43] [114]
Hydrocortisone DMGEMB7 Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [114]
Ketorolac DMI4EL5 Moderate Additive CNS depression effects by the combination of Grepafloxacin and Ketorolac. Postoperative inflammation [1A00-CA43] [96]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Grepafloxacin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [139]
Progesterone DMUY35B Moderate Decreased metabolism of Grepafloxacin caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [83]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Degarelix. Prostate cancer [2C82] [81]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Grepafloxacin and ABIRATERONE. Prostate cancer [2C82] [81]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Nilutamide. Prostate cancer [2C82] [81]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Enzalutamide. Prostate cancer [2C82] [81]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Flutamide. Prostate cancer [2C82] [81]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Bicalutamide. Prostate cancer [2C82] [81]
Silodosin DMJSBT6 Moderate Decreased metabolism of Grepafloxacin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [140]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Grepafloxacin caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [141]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Grepafloxacin and Verteporfin. Psoriasis [EA90] [85]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Fluphenazine. Psychotic disorder [6A20-6A25] [81]
Bosentan DMIOGBU Moderate Decreased metabolism of Grepafloxacin caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [142]
Axitinib DMGVH6N Moderate Decreased metabolism of Grepafloxacin caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [85]
Temsirolimus DMS104F Moderate Decreased metabolism of Grepafloxacin caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [143]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Sorafenib. Renal cell carcinoma [2C90] [81]
Meloxicam DM2AR7L Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Meloxicam. Rheumatoid arthritis [FA20] [96]
Sulindac DM2QHZU Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Sulindac. Rheumatoid arthritis [FA20] [96]
Celecoxib DM6LOQU Moderate Additive CNS depression effects by the combination of Grepafloxacin and Celecoxib. Rheumatoid arthritis [FA20] [96]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Oxaprozin. Rheumatoid arthritis [FA20] [96]
Flurbiprofen DMGN4BY Moderate Additive CNS depression effects by the combination of Grepafloxacin and Flurbiprofen. Rheumatoid arthritis [FA20] [96]
Fenoprofen DML5VQ0 Moderate Additive CNS depression effects by the combination of Grepafloxacin and Fenoprofen. Rheumatoid arthritis [FA20] [96]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [114]
Tolmetin DMWUIJE Moderate Additive CNS stimulant effects by the combination of Grepafloxacin and Tolmetin. Rheumatoid arthritis [FA20] [96]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Quetiapine. Schizophrenia [6A20] [81]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Mesoridazine. Schizophrenia [6A20] [80]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Thioridazine. Schizophrenia [6A20] [85]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Grepafloxacin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [80]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Iloperidone. Schizophrenia [6A20] [81]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Paliperidone. Schizophrenia [6A20] [81]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Perphenazine. Schizophrenia [6A20] [81]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Chlorpromazine. Schizophrenia [6A20] [81]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Trifluoperazine. Schizophrenia [6A20] [81]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Risperidone. Schizophrenia [6A20] [81]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Amisulpride. Schizophrenia [6A20] [81]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Asenapine. Schizophrenia [6A20] [81]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Pimozide. Schizophrenia [6A20] [85]
Fentanyl DM8WAHT Moderate Decreased metabolism of Grepafloxacin caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [83]
Sufentanil DMU7YEL Moderate Decreased metabolism of Grepafloxacin caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [83]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Grepafloxacin caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [144]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Vardenafil. Sexual dysfunction [HA00-HA01] [81]
LDE225 DMM9F25 Moderate Decreased metabolism of Grepafloxacin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [145]
Larotrectinib DM26CQR Moderate Decreased clearance of Grepafloxacin due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [80]
Dactinomycin DM2YGNW Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [79]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [114]
Cyclophosphamide DM4O2Z7 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [79]
Vinblastine DM5TVS3 Moderate Decreased metabolism of Grepafloxacin caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Grepafloxacin caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Docetaxel DMDI269 Moderate Decreased clearance of Grepafloxacin due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [146]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Grepafloxacin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
Armodafinil DMGB035 Minor Decreased metabolism of Grepafloxacin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [80]
Mitoxantrone DMM39BF Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [79]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Grepafloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [81]
Etoposide DMNH3PG Moderate Decreased metabolism of Grepafloxacin caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [81]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [114]
Cisplatin DMRHGI9 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Cisplatin. Solid tumour/cancer [2A00-2F9Z] [79]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [81]
Gemcitabine DMSE3I7 Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Gemcitabine. Solid tumour/cancer [2A00-2F9Z] [79]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [81]
Norethindrone DMTY169 Moderate Decreased metabolism of Grepafloxacin caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Fluorouracil DMUM7HZ Minor Decreased absorption of Grepafloxacin due to intestinal mucosa variation caused by Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [79]
Taxol DMUOT9V Moderate Decreased metabolism of Grepafloxacin caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [147]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [81]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Pitolisant. Somnolence [MG42] [81]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [81]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Grepafloxacin and Adenosine. Supraventricular tachyarrhythmia [BC81] [148]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Lenvatinib. Thyroid cancer [2D10] [81]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Cabozantinib. Thyroid cancer [2D10] [81]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Papaverine. Tonus and reflex abnormality [MB47] [149]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Tizanidine. Tonus and reflex abnormality [MB47] [81]
Sirolimus DMGW1ID Moderate Decreased metabolism of Grepafloxacin caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [80]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Grepafloxacin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [100]
Triamcinolone DM98IXF Major Increased risk of tendinitis/tendon rupture by the combination of Grepafloxacin and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [114]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Procainamide. Ventricular tachyarrhythmia [BC71] [81]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [81]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [81]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Grepafloxacin and Amiodarone. Ventricular tachyarrhythmia [BC71] [81]
⏷ Show the Full List of 326 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020695.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
6 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
7 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
8 Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 2000 Oct;295(1):146-52.
9 Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39.
12 Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
32 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
33 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
34 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
35 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
36 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
37 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
38 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
39 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
40 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
41 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
42 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
43 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
44 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
45 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
46 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
47 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
48 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
49 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
50 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
51 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
52 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
53 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
54 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
55 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
56 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
57 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
58 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
59 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
60 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
61 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
62 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
63 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
64 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
65 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
66 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
67 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
68 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
69 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
70 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
71 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
72 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
73 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
74 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
75 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
76 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
77 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
78 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
79 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
80 Cerner Multum, Inc. "Australian Product Information.".
81 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
82 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
83 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
84 Canadian Pharmacists Association.
85 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
86 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
87 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
88 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
89 Efthymiopoulos C, Bramer SL, Maroli A, Blum B "Theophylline and warfarin interaction studies with grepafloxacin." Clin Pharmacokinet 33(Suppl 1) (1997): 39-46. [PMID: 9433655]
90 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
91 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
92 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
93 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
94 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
95 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
96 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
97 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
98 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
99 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
100 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
101 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
102 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
103 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
104 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
105 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
106 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
107 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
108 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
109 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
110 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
111 Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
112 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
113 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
114 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
115 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
116 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
117 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
118 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
119 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
120 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
121 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
122 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
123 Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
124 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
125 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
126 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
127 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
128 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
129 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
130 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
131 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
132 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
133 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
134 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
135 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
136 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
137 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
138 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
139 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
140 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
141 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
142 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
143 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
144 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
145 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
146 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
147 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
148 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
149 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]